Isonics Corporation Delivers Silicon-28 Silicon-On-Insulator Wafers.

Business Editors/Hi-Tech Writers

GOLDEN, Colo.--(BUSINESS WIRE)--May 2, 2002

Isonics Corporation (Nasdaq:ISON), a leader in the development of isotopically engineered semiconductor materials and a supplier of isotopes for life sciences and health care applications, has announced that a leading semiconductor manufacturer has taken delivery of Silicon-28 Thin-Film, Silicon On Insulator (SOI) wafers for evaluation.

"While SOI wafers are known to reduce power requirements for devices, heat has been a large concern for certain applications and is expected to become an even larger, more critical consideration as chip manufacturers continue to push for more performance," said Dr. Stephen J. Burden, Isonics Vice President of Semiconductor Materials. "Semiconductor manufacturers, eager to design the optimum thermal/electrical solution for their specific device, are becoming aware of the outstanding performance offered by the marriage of our high thermal conductivity silicon-28 and the film SOI wafer technology," he added.

Isotopically purified silicon-28 has 60% higher thermal conductivity than natural silicon, allowing for reductions in the self heating of circuits made with natural SOI wafers. Incorporating Silicon-28 into SOI wafers made using either oxygen implantation or layer transfer technologies requires no change in the established manufacturing processes developed for these SOI wafers. The wafers delivered to this customer were not manufactured in Isonics thick-film SOI facility, but in cooperation with an existing thin-film SOI wafer supplier.

Further information on the availability of silicon-28 SOI or epitaxial wafers can be obtained from Isonics Corporation by contacting Dr. Burden at [phone].

About Isonics Corporation

Isonics is a world leader in isotopically engineered materials and produces isotopically pure silicon-28 chemicals and wafers and silicon-on-insulator wafers (SOI) for the semiconductor industry. Isonics also markets and sells stable isotopes for the health care industry such as carbon-13 for diagnostic breath tests and drug design, and oxygen-18 for positron emission tomography (PET) imaging. Stable isotopes can be thought of as ultra pure materials. For additional information visit http://www.isonics.com.

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein, and which may result in the parties being unable or unwilling to complete the transaction described herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's 10-KSB for the year ended April 30, 2001 as filed with the Securities and Exchange Commission, which include the Company's cash flow difficulties, dependence on significant customers, and rapid development of technology, among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.